ProCE Banner Activity


Integrating Adjuvant CDK4/6 Inhibitors Into Care of Patients With HR-Positive/HER2-Negative Early-Stage Breast Cancer

Text Module

Review this case-based module on incorporating adjuvant CDK4/6 inhibitors into the treatment of patients with HR-positive/HER2-negative early-stage breast cancer, including patient selection, toxicity management, and adherence considerations.

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurses: 0.50 Nursing contact hour

Pharmacists: 0.50 contact hour (0.05 CEUs)

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Released: May 01, 2024

Expiration: April 30, 2025



Tanya Gupta

Tanya Gupta, MD

Clinical Assistant Professor
Breast Oncology
Stanford Healthcare
Palo Alto, California

Provided by

Provided by Clinical Care Options, LLC in partnership with

ProCE Banner


Supported by educational grants from AstraZeneca, Merck Sharp & Dohme, LLC, and Novartis Pharmaceuticals Corporation.


Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation


ProCE Banner

Target Audience

This program is intended for oncologists, nurses, nurse practitioners, physician associates, pharmacists, and other healthcare professionals who care for patients with breast cancer. This educational program is also intended to reach patients with early-stage breast cancer and their caregivers.

Program Learning Goal

The goal of this program is to improve the knowledge, competence, and performance of learners to optimize treatment for patients with HER2-negative early-stage breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Appraise current/emerging published data and consensus-based guidelines to inform the use of biomarkers and genomic classifiers to assess risk of recurrence
  • Plan optimal (neo)adjuvant treatment strategies with approved targeted or immunotherapy agents for appropriate patients with EBC

  • Develop supportive care strategies to manage adverse events with current and emerging therapies for EBC to improve adherence and optimize outcomes


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Tanya Gupta, MD

Clinical Assistant Professor
Breast Oncology
Stanford Healthcare
Palo Alto, California

Tanya Gupta, MD: consultant/advisor/speaker: AstraZeneca, Biotheranostics, Gilead, Pfizer.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except Kristi K. Orbaugh, MSN, NP, AOCNP, as noted below.

Kristi K. Orbaugh, MSN, NP, AOCNP: consultant/advisor/speaker: AstraZeneca, CTI/SOBI, Daichii Sankyo, Lilly, Morphosys, Pfizer.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 01, 2024, through April 30, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.5 contact hours.

Continuing Pharmacy Education

CCO designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-24-109-H01-P

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

LogoDescription automatically generated

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until April 30, 2025. PAs should only claim credit commensurate with the extent of their participation.

CME Passport 


The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit to create your account.